.
Global Proteomics Market
.
The proteomics market size is expected to reach USD 144.7 billion by the end of 2035, growing at a CAGR of 13.68% during the forecast period (2023–2035). The proteomics industry size was USD 27.4 billion in 2022. The market growth is driven by the increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases, respiratory diseases, and chronic diseases worldwide. It is also possible to identify anticancer drugs and modify cancer treatment using tumor proteins. Proteomics is increasingly needed due to the utilization of tumor proteins in brain, colon, breast, rectum, prostate, and other tissues for cancer treatment. Proteomics can be used to identify new treatment options and diagnose cancer. According to WHO, nearly one in six deaths in 2020, or more than 10 million deaths, were related to cancer.
In addition, the increasing demand for personalized medicine and better diagnostics to treat targeted diseases, and the disproportionate incidence of targeted diseases are the major drivers of the growing demand for proteomics. Prevention is becoming dominant in healthcare. The high accuracy and sensitivity of mass spectrometry studies on proteomes are well suited to integrating proteomics into precision medicine. According to NCBI, the future of personalized medicine lies in the use of proteomics in hospitals. The efficient application of personalized proteomics to diagnose and treat conditions depends on the appropriate translation of scientific discoveries into medical practice. Precision medicine aims to ensure that each patient achieves the best possible outcome by more accurately and effectively connecting the most appropriate treatment regimen. Rapid proteomics testing on easily accessible tissue samples enables early diagnosis of disease status and severity, as well as improved patient outcomes, allowing healthcare providers to respond more quickly in emergency situations. The advantages of personalized proteomics have led to the rapid growth of this proteomics market.
Growth drivers
Challenge
|
기준 연도 |
2023 |
|
예측 연도 |
2024-2036 |
|
CAGR |
13.7% |
|
기준연도 시장 규모(2023년) |
311억 5천만 달러 |
|
예측 연도 시장 규모(2036년) |
1,653억 5천만 달러 |
|
지역 범위 |
|
Components (instruments, reagents, software and services)
The reagents segment of the proteomics market is expected to grow significantly at a CAGR of 13.42% from 2022 to 2035, reaching USD 97.4 billion by 2035. The segment was valued at USD 19 billion in 2022. The growth of the segment can be attributed to the high demand for reagents and consumables due to the extensive use of kits, chemicals, strips, reagents, and consumables and other materials for analyzing various biological samples in research laboratories, academic institutions, and other settings. Proteomics studies are complex and multidisciplinary, which leads to a high demand for high-quality chemical reagents. Mass spectrometry (MS)-based proteomics studies have utilized novel chemicals and methodologies. The goal of synthesizing many chemicals, including peptides and proteins, is to covalently link them to biomolecules.
Application (clinical diagnosis, new drug development)
The proteomics market in the drug discovery segment was valued at over USD 12.7 billion in 2022 and is expected to reach USD 68.7 billion by 2035, growing at a significant CAGR of 13.88% during the forecast period. The drug discovery category is expected to grow at the fastest rate during the forecast period. The growth of this market can be attributed to advancements in structure-based drug design, increasing focus on personalized drug development, and increasing financial support for such initiatives. Additionally, proteomics technology provides a means to demonstrate early in the drug discovery program. This saves a lot of costs for pharmaceutical companies and ultimately aids the growth of the sector by supporting patients and healthcare systems.
The in-depth analysis of the global market includes the following segments:
|
element |
|
|
Application |
|
|
End User |
|
North American Market Outlook
프로테오믹스 시장 규모는 2023년에 311억 5천만 달러 이상이었고 2036년 말까지 1,653억 5천만 달러를 넘어 예측 기간(2024~2036년) 동안 CAGR 13.7% 이상 성장할 것으로 예상됩니다. 2024년 프로테오믹스 산업 규모는 349억 9천만 달러로 추산된다. The proteomics products market is growing due to the increasing adoption of bispecific antibody conjugates and protein therapeutics in North America for the treatment and diagnosis of diseases. Ten ADCs have already received FDA approval in the US, and more than 90 ADCs are in clinical development globally. Several clinical indications that have recently been approved for recombinant protein therapies include cancer, autoimmune/inflammation, exposure to infectious agents, and genetic diseases. Proteomics is being widely used in antibody-drug conjugates and protein therapeutics in North America, which is driving the demand for proteomics products and facilitating the rapid expansion of the market.
European Market Statistics
The European proteomics market is expected to expand at a CAGR of 13.21% from 2022 to 2035. The European market is expected to grow from USD 7.2 billion in 2022 to USD 36.2 billion by the end of 2035. The market demand is increasing due to technological improvements, government support for proteomics, and increasing research and spending in Europe. The increasing prevalence of chronic diseases such as cancer, heart disease, respiratory diseases, and other diseases is also accelerating the market growth in Europe. The World Health Organization (WHO) estimates that 60 million people (10.3% of men and 9.6% of women aged 25 years and above) suffer from diabetes in the European region. Diabetes is becoming increasingly common across all age groups in the European region, mainly due to the rise in overweight and obesity, poor dietary habits, and lack of physical activity. These proteomics benefits are driving the growth of the industry.
.
.
저자 크레딧: Radhika Pawar
무료 샘플 사본에는 시장 개요, 성장 추세, 통계 차트 및 표, 예상 예측 등이 포함됩니다.
이 보고서를 주문하기 전에 질문이 있으십니까?